ERBB2 and neoplasm: With the use of distinct HER2+ BC cell lines and PBMC from several human donors, this work attempts to better mimic patient heterogeneity, which can be further achieved by using patient-derived PBMCs or even ex vivo approaches with patient tumor samples (141).